Assistance Publique-hopitaux De Paris

Sorbonne Université

Institut National De La Sante Et De La Recherche Medicale

Université Pierre Et Marie Curie (Paris Vi)

Université Pierre Et Marie Curie (Paris 6)

Université Pierre Et Marie Curie

Other

Centre National De La Recherche Scientifique

Consejo Nacional De Investigaciones Cientificas Y Tecnicas (conicet)

Institut Pasteur

Universitè De Montpellier

Rhone-poulenc, Inc.

Aventis Pharma S.a.

Centre National De La Recherche Scientifique-cnrs

Cnrs

David Klatzmann

Jean-Loup Salzmann

Eliane Piaggio

Patrice Cacoub

Bertrand Bellier

Claude Bernard

Gilbert Bensimon

Michèle Rosenzwajg

David Saadoun

Patrice Yeh

Jacques Cohen

Hugo Daniel Lujan

Luc Montagnier

Michel Perricaudet

Reinhard Fleer

David E Anderson

Francois-Loic Cosset

Philippe Kourilsky

Robert C Nowinski

Anne-Catherine Fluckiger

Claude Roth

Lluis M Mir

Marcos Steinberg

Gilles Marodon

Christophe Torrent

Jean-Francedillaois Mayaux

Cedric Mongellaz

José Cohen

Olivier Boyer

Didier Landais

Philippe Hirel

Jerome Becquart

François Lemoine

Patrick Salmon

Manuel Caruso

Benoit Salomon

Nicolas Billiald

Thomas Vazquez

Jérémie Mariau

Paul-Gydéon Ritvo

Encarnita Mariotti-Ferrandiz

Andr&egrave;s Crespo

Charlotte Dalba-Fribert

Michéle Rosenzwajg

Hugo Daniel Luján

Charlotte Fribert

Charlotte Frisen

François-Loïc Cosset

Naomi Sitbon

Oumeya Adjali

Chantal Jacquet

Sébastien Maury

Roberta Lorenzon

Arsene Mekinian

Georg Holzer

Arnaud Morel

Norbert Passuti

François-Loic Cosset

Theodora Hatziiannou

The invention relates to a virus-like particle comprising an allergen and an immunoregulatory molecule exposed on its surface. The invention also relates to the use of said particle in the treatment of an allergy.

Virus-like particles which can be used in the treatment of allergies

The present invention relates to a combination of i) interleukin-2 (IL-2) and ii) an interleukin 1 (IL-1) inhibitor, for use in treating an auto-immune and/or inflammatory disorder in a subject. It is also provided a pharmaceutical composition comprising interleukin-2 (IL-2) and an interleukin-1 (IL-1) inhibitor. The invention further provides a conjugate comprising IL-2 conjugated to an IL-1 inhibitor.

Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof

The invention relates to a composition comprising regulatory T (Treg) cells or effector T cells (Teff) which stably express an interleukin selected from the group consisting of interleukin-2 (IL-2) or interleukin-15 (IL-15).

Genetically modified T lymphocytes

The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.

Use of low dose IL-2 for treating autoimmune-related or inflammatory disorders

The invention relates to the use of interleukin-2 in treating Sj&#xf6;gren's syndrome in a subject, wherein IL-2 is to be administered at a low dose of less than about 3.5 MIU/day.

Use of interleukin 2 for treating Sj&#xf6;gren's syndrome

The invention relates to a virus-like particle comprising an autoantigen and an immunoregulatory molecule exposed on its surface. The invention also relates to the use of said particle in the treatment of an autoimmune disease.

Virus-like particles which can be used in the treatment of autoimmune diseases

The present disclosure provides compositions and methods useful for treating HCMV infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more HCMV epitopes, such as, for example, from HCMV envelope glycoproteins gB and/or gH and/or tegument protein pp65. Among other things, the present invention encompasses the recognition that a combination of antigens (e.g., envelope glycoproteins and structural proteins) can lead to beneficial immune responses, for example that include both a humoral response (e.g., production of neutralizing antibodies) and a cellular response (e.g., T-cell activation).

Compositions and methods for treatment of cytomegalovirus

Use of low dose IL-2 for treating autoimmune&#x2014;related or inflammatory disorders

The present invention relates to the use of interleukin-2 (IL-2) for treating a food allergy, either by inducing non-specific tolerance against food allergens, or in a desensitization protocol in combination with a food allergen.

Interleukin-2 for treating food allergy

Use of low dose IL-2 for treating autoimmune related or inflammatory disorders

The invention relates to pharmaceutical compositions using a polypeptide comprising at least one CXXC motif, such asparasite's variable surface proteins (VSP) or a fragment thereof to raise by oral or mucosal vaccination an immune response against a heterologous selected antigen, such as tumor antigen, microbial antigen or other antigen.

Pharmaceutical compositions comprising a polypeptide comprising at least one CXXC motif and heterologous antigens and uses thereof

The present invention relates to compositions and methods for producing an immune response or reaction, as well as to vaccines, kits, processes, cells and uses thereof. This invention more particularly relates to compositions and methods of using a synthetic viral particle to produce, modify or regulate an immune response in a subject. In a more preferred embodiment, the invention is based, generally, on compositions using synthetic viral particles as an adjuvant and/or vehicle to raise an immune response against selected antigen(s) or epitopes, in particular a cellular and/or a humoral immune response.

Synthetic viruses and uses thereof

The invention provides compositions for oral delivery and methods of treatment using VSP carriers, such assp. variable surface proteins (VSP), to deliver therapeutic agents. VSP drug carriers can be combined with bioactive peptides, e.g., insulin, glucagon, or hGH, and be administered orally or mucosally. VSP carriers are resistant to acidic pHs and to proteolytic degradation and protect therapeutic agents from degradation in the gastrointestinal tract.

Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery

Method for stimulating T lymphocytes with IL-2

Growing community of inventors

Paris, France

David Klatzmann